Physician profile
Joseph Benevenia
NPI 1710911102
$174,439.36
in general payments reported to CMS, 2019-2025
10 companies · $27K in 2025
The $27K reported for 2025 was more than what 93% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $14K · 2021: $26K · 2022: $31K · 2023: $27K · 2024: $34K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $88K · Food and Beverage: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $87,728.27 |
| Food and Beverage | $371.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merete Technologies, INC | $172,008.07 | 2019-2025 | |
| Onkos Surgical, INC. | $1,584.36 | 2019-2022 | |
| Bone Support INC. | $230.71 | 2021 | |
| Zimmer Biomet Holdings, INC. | $145.00 | 2024 | Affixus |
| Medtronic USA, INC. | $136.16 | 2019 | |
| Innovation Technologies INC | $108.75 | 2023 | Irrisept |
| Stryker Corporation | $101.62 | 2019 | |
| Heraeus Medical, LLC. | $62.96 | 2024 | |
| Illuminoss Medical, INC. | $47.74 | 2022-2023 | Photodynamic Bone Stabilization Procedure Pack |
| Vertex Pharmaceuticals Incorporated | $13.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Benevenia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.